February 1, 2018

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients

Health-related quality of life was maintained for a longer period of time in several predefined health scales in EF-14 trial patients treated with a combination of Optune and temozolomide compared to patients treated with temozolomide alone The use of Optune together with temozolomide extended progression free and… Read More
learn more
February 1, 2018

JAMA Oncology Publishes EF-14 Pivotal Trial Analysis Showing Optune Plus Temozolomide Improved Survival without Negatively Influencing Health-Related Quality of Life Compared to Temozolomide Alone in Newly Diagnosed GBM Patients

Health-related quality of life was maintained for a longer period of time in several predefined health scales in EF-14 trial patients treated with a combination of Optune and temozolomide compared to patients treated with temozolomide alone The use of Optune together with temozolomide extended progression free and… Read More
learn more
January 9, 2018

Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue

1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016 Fourth quarter 2017 preliminary net revenues of $53.7 million, reflecting 77 percent growth versus fourth quarter 2016 Fourth quarter and full year 2017 financial results to be reported Thursday,… Read More
learn more
January 9, 2018

Novocure Announces Fourth Quarter and Full Year 2017 Operating Statistics and Preliminary Revenue

1,834 active patients at December 31, 2017, an increase of 68 percent versus December 31, 2016 Fourth quarter 2017 preliminary net revenues of $53.7 million, reflecting 77 percent growth versus fourth quarter 2016 Fourth quarter and full year 2017 financial results to be reported Thursday,… Read More
learn more